# MAZE catalysts: Maze Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/maze/catalysts

> Maze Therapeutics, Inc. (MAZE) has 6 upcoming catalysts. The next is the MZE829 trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MAZE?

Maze Therapeutics, Inc. (MAZE) has 6 upcoming catalysts. The next is the MZE829 trial start, 1H 2027. SEC Form 10-Q: "In addition, we plan to initiate a pivotal trial of MZE829 in the first half of 2027, subject to regulatory feedback." [Calendar and source filings](https://sec-api.dev/companies/maze/catalysts)

Source: SEC Form 10-Q, accession 0001193125-26-453619, https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/maze/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Maze Therapeutics, Inc. |
| Ticker | MAZE (Nasdaq) |
| SEC CIK | 1842295 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/maze |

## Cash runway

Cash $477.0M as of 2026-09-30; quarterly burn $32.8M; about 43.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-453619).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [MZE782 trial start](https://sec-api.dev/pdufa/mze782) | MAZE |  | completed | "In September 2024, Maze initiated a Phase 1 clinical trial of MZE782 in healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm)) |
| Nov 2024 | [MZE829 topline data readout](https://sec-api.dev/pdufa/mze829) | MAZE |  | completed, positive | "We initiated a Phase 2 trial of MZE829, our most advanced lead program, in November 2024, dosed our first patient in February 2025 and reported positive topline clinical proof of concept data in March 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm)) |
| Nov 2024 | [MZE829 trial start](https://sec-api.dev/pdufa/mze829) | MAZE |  | completed | "We initiated a Phase 2 trial of MZE829 in November 2024 and dosed our first patient in February 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm)) |
| Feb 2025 | [MZE829 topline data readout](https://sec-api.dev/pdufa/mze829) | MAZE |  | completed, positive | "February 2025 and reported positive topline clinical proof of concept data in March 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526170687/d15217d424b5.htm)) |
| Feb 2025 | [MZE829 trial start](https://sec-api.dev/pdufa/mze829) | MAZE |  | completed | "In February 2025, Maze dosed the first patient in the Phase 2 HORIZON Study of MZE829 in patients with AKD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm)) |
| March 31, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm)) |
| May 14, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/maze-ex99_1.htm)) |
| Q3 2025 | [MZE782 interim data readout](https://sec-api.dev/pdufa/mze782) | MAZE |  | scheduled | "Maze expects to report initial data, including biomarker and proof-of-mechanism results relevant for both indications, in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-ex99_1.htm)) |
| 2H 2025 | [MZE782 trial start](https://sec-api.dev/pdufa/mze782) | MAZE |  | scheduled | ""We look forward to reporting initial Phase 1 data for MZE782 in healthy volunteers in the second half of 2025, which will enable us to prepare to initiate Phase 2 trials in CKD and PKU." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm)) |
| August 12, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-ex99_1.htm)) |
| November 6, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/maze-ex99_1.htm)) |
| Q1 2026 | [MZE829 interim data readout](https://sec-api.dev/pdufa/mze829) | MAZE |  | scheduled | "MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with APOL1-Mediated Kidney Disease; Initial Data Expected in Q1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-ex99_1.htm)) |
| Q1 2026 | [Maze Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | scheduled | "Maze expects to report topline proof-of-concept data from the Phase 2 HORIZON trial by the end of the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/maze-ex99_1.htm)) |
| Mar 2026 | [Maze Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed, positive | "In March 2026, we announced positive topline results from our" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526170687/d15217d424b5.htm)) |
| March 13, 2026 | [MZE001 trial start](https://sec-api.dev/pdufa/mze001) | MAZE |  | completed | "On March 13, 2026, the Company received notification from Shionogi that the first patient has been dosed in the Phase 2 study of MZE001 for Pompe disease." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/maze-20251231.htm)) |
| March 24, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-ex99_1.htm)) |
| March 24, 2026 | [MZE829 topline data readout](https://sec-api.dev/pdufa/mze829) | MAZE |  | completed, positive | "Today, Maze announced positive topline data from the Phase 2 HORIZON trial evaluating MZE829 in patients with broad AMKD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-ex99_1.htm)) |
| mid-2026 | [MZE782 trial start](https://sec-api.dev/pdufa/mze782) | MAZE | PKU and patients with CKD | scheduled | "Maze plans to initiate two Phase 2 proof-of-concept trials of MZE782 evaluating plasma phenylalanine (Phe) reduction in PKU and proteinuria reduction in CKD by mid-2026 and in the second half of 2026, respectively." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-ex99_1.htm)) |
| May 12, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-ex99_1.htm)) |
| August 11, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm)) |
| September 2026 | [MZE829 primary completion](https://sec-api.dev/pdufa/mze829) | MAZE | Proteinuric Kidney Disease | delayed | "NCT06830629 (A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Maze Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830629)) |
| Sep to Dec 2026 | [MZE829 topline data readout](https://sec-api.dev/pdufa/mze829) | MAZE | Proteinuric Kidney Disease | scheduled | "NCT06830629 (A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Maze Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830629)) |
| November 9, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm)) |
| 1H 2027 | [MZE829 trial start](https://sec-api.dev/pdufa/mze829) | MAZE |  | scheduled | "In addition, we plan to initiate a pivotal trial of MZE829 in the first half of 2027, subject to regulatory feedback." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm)) |
| 2027 | [MZE782 interim data readout](https://sec-api.dev/pdufa/mze782) | MAZE |  | scheduled | ""The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in 2027, and continued strong enrollment in the Phase 2 HORIZON trial of MZE829 across three cohorts with additional data on track for 10-15 patients per cohort in late 2026 or early 2027," said Jason Coloma, Ph.D., chief executive officer of Maze." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm)) |
| early 2027 | [MZE829 interim data readout](https://sec-api.dev/pdufa/mze829) | MAZE |  | scheduled | "We are encouraged by the previously reported clinically meaningful uACR reductions demonstrated among 12 efficacy-evaluable patients in an interim data cut from HORIZON, look forward to reporting the complete HORIZON dataset in early 2027, and plan to use these results to inform our pivotal program." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm)) |
| 1H 2027 | [MZE782 trial start](https://sec-api.dev/pdufa/mze782) | MAZE |  | scheduled | "We are also making strong progress with MZE782 with respect to both continued enrollment in the Phase 2 CIPheR trial in PKU and advancement of our plans to initiate a Phase 2 CKD trial in the first half of 2027."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm)) |
| December 2027 | [MZE782 primary completion](https://sec-api.dev/pdufa/mze782) | MAZE | Phenylketonuria (PKU) | scheduled | "NCT07694440 (A Study of MZE782 in Adults With PKU): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Maze Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07694440)) |
| Dec 2027 to Mar 2028 | [MZE782 topline data readout](https://sec-api.dev/pdufa/mze782) | MAZE | Phenylketonuria (PKU) | scheduled | "NCT07694440 (A Study of MZE782 in Adults With PKU): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Maze Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07694440)) |

## Drugs

- [MZE001](https://sec-api.dev/pdufa/mze001): 
- [MZE782](https://sec-api.dev/pdufa/mze782): phenylketonuria, or pku, pku in 2027, pku and in patients with ckd in 2026, pku and patients with ckd, pku in mid-2026, Phenylketonuria (PKU)
- [MZE829](https://sec-api.dev/pdufa/mze829): broad amkd, kidney and metabolic diseases, today, Proteinuric Kidney Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/maze/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MAZE catalysts: Maze Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/maze/catalysts

```bibtex
@misc{secapidev_companies_maze_catalysts_20261116,
  title        = {MAZE catalysts: Maze Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/maze/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_maze_catalysts_20261116","title":"MAZE catalysts: Maze Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/maze/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
